Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:31:05.194Z.
Calculation as of: 2026-10-06T16:31:05.194Z.
Quote observation: 2026-10-06T16:30:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92e82853ec35d591c91e1857ba5f245e9338475f566e1ab86be3b7c1b83139db
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Artiva Biotherapeutics, Inc.
Market Cap
$354.70M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$355.36M
EBITDA Yield
N/A
TTM Avg
3.23%
3Y Avg
3.23%
5Y Avg
3.23%
Market Cap
$349.40M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$359.33M
EBITDA Yield
N/A
TTM Avg
3.28%
3Y Avg
4.15%
5Y Avg
7.65%
Market Cap
$374.75M
EBITDA Yield
N/A
TTM Avg
0.15%
3Y Avg
0.15%
5Y Avg
0.15%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $354.70M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.36M | N/A | 3.23% | 3.23% | 3.23% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $353.30M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $359.46M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.40M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $359.33M | N/A | 3.28% | 4.15% | 7.65% |
| Embecta Corp. (EMBC)vs › | $359.53M | 18.53% | 21.70% | 14.93% | 15.13% |
| Opus Genetics, Inc. (IRD)vs › | $363.54M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $374.75M | N/A | 0.15% | 0.15% | 0.15% |
| Agenus Inc. (AGEN)vs › | $333.02M | 11.53% | 6.91% | 6.91% | 10.15% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
